Remove 2019 Remove Diabetes Remove Individual Remove Management
article thumbnail

Outcomes associated with timing of screening for gestational diabetes [Women's health]

Annals of Family Medicine

Context: Screening for gestational diabetes (GDM) at recommended times, based on a pregnant woman’s risk for GDM, is important in order to initiate and optimize the management of GDM as early as possible, thus mitigating the risk of several adverse outcomes for both pregnant women and their offspring.

Screening 130
article thumbnail

Preemies receive sucrose for pain relief—new research shows it doesn't stop long-term impacts on development

Medical Xpress

The commonest strategy to manage acute pain in preterm babies is to give them sucrose , a sugar solution. One of these sites does not use sucrose for acute pain management. We found no link between preterm babies later behavior and how much sucrose they were given to manage pain. Whats more, pain isnt always managed.

IT 53
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Identifying and Resolving Red Flags: DEA Continues to “Run it Up the Flagpole”

FDA Law

DEA regulations state that a pharmacist has a corresponding responsibility not to fill a prescription unless it is issued for a “legitimate medical purpose by an individual practitioner acting in the usual course of [their] professional practice.” 12, 2012) (quoting Bob’s Pharmacy & Diabetic Supplies; Revocation of Registration, 74 Fed.

IT 40
article thumbnail

Patient Groups Sue HHS, CMS for 2020 Rule Allowing the Use of Copay Accumulator Programs

FDA Law

As it stands, the rule allows insurers and pharmacy benefit managers (PBMs) to broadly use copay accumulator programs, which have long been criticized by patient advocacy groups as padding insurers’ pockets while leaving patients high and dry. During the Trump administration, HHS and CMS issued the 2020 NBPP rule , revising 45 C.F.R.

article thumbnail

Drug Pricing Reform Gathers Steam (Part 1): White House Drug Pricing Plan Offers Laundry List of Existing Democrat Priorities

FDA Law

A final OIG rule to change the structure of manufacturer rebates to Medicare Part D and Medicaid Managed Care plans and their PBMs is enmeshed in litigation and is likely to be at least postponed until 2026 (see our post ), and perhaps prevented from implementation altogether, by Congressional mandate.